CTBP2 antibody (full length)

Catalog No. ABIN7877731

The Mouse Monoclonal anti-CTBP2 antibody (Clone PCRP-CTBP2-1A9) (ABIN7877731) specifically detects CTBP2 in IF and FACS. The antibody is reactive with Human samples.

Quick Overview for CTBP2 antibody (full length) (ABIN7877731)

Target: CTBP2 (C-terminal Binding Protein 2 (CTBP2))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This CTBP2 antibody is un-conjugated

Application: Immunofluorescence (IF), Flow Cytometry (FACS)

Grade: Carrier-free

Clone: PCRP-CTBP2-1A9

Product Details anti-CTBP2 Antibody

Binding Specificity: full length

Purpose: CTBP2 Antibody / C-terminal-binding protein 2 (azide and preservative free)

Purification: Protein A/G affinity

Immunogen: Recombinant full-length human CTBP2 protein was used as the immunogen for the CTBP2 antibody.

Isotype: IgG2b

Application Details

Application Notes: Optimal dilution of the CTBP2 antibody should be determined by the researcher.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Preservative: Azide free

Storage: -20 °C

Storage Comment: Aliquot the CTBP2 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.

Target Details for CTBP2

Target: CTBP2 (C-terminal Binding Protein 2 (CTBP2))

Alternative Name: CTBP2

Background: The gene CTBP2 (C-terminal binding protein 2) encodes a member of the CtBP-family. The gene is mapped to human chromosome 21q21.3. It is found to be expressed ubiquitously, with higher expression in the heart, skeletal muscle, and pancreas. The gene CTBP2 (C-terminal binding protein 2) encodes a protein that functions as a transcriptional co-repressor of several tumor suppressor genes resulting in enhanced cancer cell migration and invasion. Its expression is found to be upregulated in hepatocellular carcinoma (HCC). It may be a potential prognostic marker for post liver resection HCC. It is involved in several types of tumor initiation, progression and response to therapy. It is found to interact with the C-terminal region of adenovirus type 2/5 E1A protein, a region that negatively regulates tumorigenicity and the extent of oncogenic transformation.

UniProt: P56545